The contribution of dendritic cells to immune responses against urological cancers

Urologic Oncology

Volumn 4, Issue 1, 1998, Pages 17-23

  Troy, Andrew ^a   Davidson, Peter ^a   Atkinson, Christopher ^a   Hart, Derek ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Dendritic cells; Immunotherapy; Tumor immunology

Indexed keywords

CD1 ANTIGEN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HUMAN; IMMUNOHISTOLOGY; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE ACTIVATION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER;

EID: 0032450615     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(98)00027-1     Document Type: Article

References (67)

1. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:1991;271-296.
2. Hart D.N.J. Dendritic cells. unique leucocyte populations which control the primary immune response Blood. 90:1997;3245-3287.
3. Boon T., Cerottini J.C., Eynde B., Bruggen P., Pel A.V. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 12:1994;337-375.
4. Troy A.J., Hart D.N.J. Dendritic cells in cancer. progress towards a new cellular therapy J Hematother. 6:1997;523-533.
5. Davis A.L., McKenzie J.L., Hart D.N.J. HLA-DR positive leukocyte subpopulations in human skin include dendritic cells, macrophages and CD7-negative T cells. Immunology. 65:1988;573-581.
6. Nestle F.O., Zheng X., Thompson C.B., Turka L.A., Nickoloff B.J. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol. 151:1993;6535-6545.
7. Roake J.A., Rao A.S., Morris P.J., Larsen C.P., Hankins D.F., Austyn J.M. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide tumor necrosis factor and interleukin 1. J Exp Med. 181:1995;2237-2247.
8. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. 8:1996;348-354.
9. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 15:1997;821-850.
10. Adema G.J., Hartgers F., Verstraten R.et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 387:1997;713-717.
11. Guinan E.C., Gribben J.G., Boussiotis V.A., Freeman G.J., Nadler L.M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 84:1994;3261-3282.
12. Schwartz R.G. Models of T cell anergy. is there a common molecular mechanism? J Exp Med. 184:1996;1-8.
13. Sorg R.V., McLellan A.D., Hock B.D., Fearnley D.B., Hart D.N.J. Human dendritic cells express functional interleukin-7. Immunobiology. 198:1998;26-38.
14. Heufler C., Koch F., Stanzl U.et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol. 26:1996;659-668.
15. Mehrotra P.T., Grant A.J., Siegel J.P. Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol. 154:1995;5093-5102.
16. Kahn H.J., Marks A., Thom H., Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol. 79:1983;341-347.
17. Bigotti G., Coli A., Castagnola D. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate. 19:1991;73-87.
18. Ohmori T., Okada K., Arita N., Watanabe Y., Miyazaki T. Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol Histopathol. 10:1995;789-794.
19. Inoue K., Furihata M., Ohtsuki Y., Fujita Y. Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis. Pathol Anat Histopathol. 422:1993;351-355.
20. Ambe K., Mori M., Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer. 63:1989;496-503.
21. Tsujitani S., Kakeji Y., Watanabe A., Kohnoe S., Maehara Y., Sugimachi K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer. 66:1990;2012-2016.
22. Troy A.J., Summers K.L., Davidson P.J.T., Atkinson C.A., Hart D.N.J. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 4:1998;585-593.
23. Troy AJ, Davidson PJT, Atkinson CH, Hart DNJ. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J Urol (In press).
24. Troy A.J., Davidson P., Atkinson C., Hart D. Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J Urol. 160:1998;214-219.
25. Hart D.N.J., Fuggle S.V., Williams K.A., Fabre J.W., Ting A., Morris P.J. Localization of HLA-ABC and DR antigens in human kidney. Transplantation. 31:1981;428-433.
26. Prickett T.C.R., McKenzie J.L., Hart D.N.J. Characterization of human interstitial dendritic cells in liver. Transplantation. 46:1988;754-761.
27. Egner W., Andreesen R., Hart D.N.J. Allostimulatory cells in fresh human blood. heterogeneity in antigen presenting cell populations Transplantation. 56:1993;945-950.
28. Zhou L.J., Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 154:1995;3821-3835.
29. Mosialos G., Birkenbach M., Ayehunie S.et al. Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein. Am J Pathol. 148:1996;593-600.
30. Hock B.D., Starling G.C., Daniel P.B., Hart D.N.J. Characterisation of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology. 83:1994;573-581.
31. Fearnley D.B., McLellan A.D., Mannering S.I., Hock B.D., Hart D.N.J. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody. implications for studies on antigen presenting cell function and immunotherapy Blood. 89:1997;3708-3716.
32. Ioachim-Velogianni E., Stavropoulos N.E., Kitsiou E., Stefanaki S., Agnantis N.J. Distribution of CD1A-positive langerhans cells and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J Pathol. 177:1995;401-406.
33. Papadimitriou C.S., Datseris G., Costopoulos J.S., Bai M.K., Ioachim-Velogianni E., Katsouyannopoulos V. Langerhans cells and lymphocyte subsets in human gastrointestinal carcinomas. An immunohistological study on frozen sections. Pathol Res Pract. 188:1992;989-994.
34. Strunk D., Egger C., Leitner G., Hanau D., Stingl G. A skin homing molecule defines the Langerhans cell progenitor in human peripheral blood. J Exp Med. 185:1997;1131-1136.
35. Imai Y., Yamakawa M. Dendritic cells in esophageal cancer and lymph node tissues. In Vivo. 7:1993;239-248.
36. Sozzani S., Luini W., Borsatti A.et al. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol. 159:1997;1993-2000.
37. Golumbek P., Levitsky H., Jaffee L., Pardoll D.M. The antitumor immune response as a problem of self-nonself discrimination. implications for immunotherapy Immunol Rev. 12:1993;183-192.
38. Knoefel B., Nuske K., Steiner T.et al. Renal cell carcinomas produce IL-6, I-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast information. J Interferon Cytokine Res. 17:1997;95-102.
39. Maffezzini M., Simonato A., Fortis C. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate. 28:1996;282-286.
40. Willems F., Marchant A., Delville J.et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol. 24:1994;1007-1009.
41. Groux H., Bigler M., de Vries J.E., Roncarolo M. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 184:1996;19-29.
42. Lipscomb M.F., Pollard A.M., Yates J.L. A role for TGF-beta in the suppression by murine bronchoalveolar cells of lung dendritic cell initiated immune responses. Reg Immunol. 5:1993;151-157.
43. Ivanovic V., Melman A., Davis-Joseph B., Valcic M., Geliebter J. Elevated plasma levels of TGF-beta1 in patients with invasive prostate cancer. Nat Med. 1:1995;282-283.
44. Eder I.E., Stenzl A., Hobisch A., Cronauer M.V., Bartsch G., Klocker H. Expression of transforming growth factors beta-1, beta-2 and beta-3 in human bladder carcinomas. Br J Cancer. 75:1997;1753-1760.
45. Belldegrun A., Pierce W., Kaboo R.et al. Interferon-a primed tumor-infiltating lymphocytes combined with interleukin-2 and interferon-a as therapy for metastatic renal cell carcinoma. J Urol. 150:1993;1384-1390.
46. Inaba K., Schuler G., Witmer M.D., Valinsky J., Atassi B., Steinman R.M. Immunologic properties of purified epidermal Langerhans cells. J Exp Med. 164:1986;605-613.
47. Chaux P., Favre N., Martin M., Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer. 72:1997;619-624.
48. Gabrilovich D.I., Nadaf S., Corak J., Berzofsky J.A., Carbone D.P. Dendritic cells in antitumor immune responses. Cell Immunol. 170:1996;111-119.
49. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 3:1997;483-490.
50. Gabrilovich D.I., Chen H.L., Girgis K.R.et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103.
51. Brown L.F., Berse B., Jackman R.W.et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 143:1993;1255-1263.
52. O'Brien T., Cranston D., Fuggle S., Bicknell R., Harris A.L. Different angiogenic pathways characterized superficial and invasive bladder cancer. Cancer Res. 55:1997;510-513.
53. Jackson M.W., Bentel J.M., Tilley W.D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 157:1997;2323-2328.
54. Ferrer A.F., Miller L.J., Andrawis R.I.et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. in situ and in vitro expression of VEGF by human prostate cancer cells J Urol. 157:1997;2329-2333.
55. Tjoa B., Erickson S., Barren R.et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate. 27:1995;63-69.
56. Radmayr C., Bock G., Hobisch A., Klocker H., Bartsch G., Thurnher M. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int J Cancer. 63:1995;627-632.
57. Maeurer MJ, Gollin SM, Martin D, et al. Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98:1633-41.
58. Adams D.H., Yannelli J.R., Newman W.et al. Adhesion of tumour-infiltrating lymphocytes to endothelium. a phenotypic and functional analysis Br J Cancer. 75(10):1997;1421-1431.
59. Becker J.C., Termeer C., Schmidt R.E., Brocker E.B. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol. 151(12):1997;7224-7232.
60. Strand S., Hofmann W.J., Hug H.et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med. 2:1996;1361-1366.
61. Walker P.R., Saas P., Dietrich P. Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back J Immunol. 158:1997;4521-4524.
62. Nagata S. Fas ligand and immune evasion. Nat Med. 2:1996;1306-1307.
63. Young J.W., Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med. 183:1996;7-11.
64. Tjoa B., Boynton A., Kenny G., Ragde H., Misrock S.L., Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 28:1996;65-69.
65. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial. T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen Prostate. 29:1996;371-380.
66. Correale P., Walmsley K., Nieroda C.et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 89:1997;293-300.
67. Shurin M.R. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother. 43:1996;158-164.